Y

Y-mAbs Therapeutics
D

YMAB

5.71500
USD
-0.31
(-5.07%)
مغلق
حجم التداول
12,661
الربح لكل سهم
-1
العائد الربحي
-
P/E
-11
حجم السوق
255,969,569
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    G
    GLPG
    0.055
    (0.21%)
    26.765 USD
    I
    IMAB
    0.01000
    (1.04%)
    0.97000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    V
    VIR
    -0.22000
    (-2.24%)
    9.58000 USD
    المزيد
الأخبار
المقالات

العنوان: Y/mAbs Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.